LT3107914T - Pirazolo[1,5-a]pirimidin-5,7-diamino junginiai kaip cdk inhibitoriai ir jų terapinis panaudojimas - Google Patents

Pirazolo[1,5-a]pirimidin-5,7-diamino junginiai kaip cdk inhibitoriai ir jų terapinis panaudojimas

Info

Publication number
LT3107914T
LT3107914T LTEP15706282.9T LT15706282T LT3107914T LT 3107914 T LT3107914 T LT 3107914T LT 15706282 T LT15706282 T LT 15706282T LT 3107914 T LT3107914 T LT 3107914T
Authority
LT
Lithuania
Prior art keywords
pyrazolo
pyrimidine
therapeutic use
diamine compounds
cdk inhibitors
Prior art date
Application number
LTEP15706282.9T
Other languages
English (en)
Inventor
Alexander BONDKE
Sebastian KROLL
Anthony Barrett
Matthew FUCHTER
Brian SLAFER
Simak Ali
Charles COOMBES
James Patrick Snyder
Original Assignee
Cancer Research Technology Limited
Ip2Ipo Innovations Limited
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Limited, Ip2Ipo Innovations Limited, Emory University filed Critical Cancer Research Technology Limited
Publication of LT3107914T publication Critical patent/LT3107914T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP15706282.9T 2014-02-21 2015-02-20 Pirazolo[1,5-a]pirimidin-5,7-diamino junginiai kaip cdk inhibitoriai ir jų terapinis panaudojimas LT3107914T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use
PCT/GB2015/050494 WO2015124941A1 (en) 2014-02-21 2015-02-20 Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use

Publications (1)

Publication Number Publication Date
LT3107914T true LT3107914T (lt) 2019-05-27

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15706282.9T LT3107914T (lt) 2014-02-21 2015-02-20 Pirazolo[1,5-a]pirimidin-5,7-diamino junginiai kaip cdk inhibitoriai ir jų terapinis panaudojimas

Country Status (22)

Country Link
US (4) US9932344B2 (lt)
EP (1) EP3107914B8 (lt)
JP (1) JP6498212B2 (lt)
CN (1) CN106103445B (lt)
AU (1) AU2015220560B2 (lt)
BR (1) BR112016018633B1 (lt)
CA (1) CA2939786C (lt)
CY (1) CY1121588T1 (lt)
DK (1) DK3107914T3 (lt)
ES (1) ES2721268T3 (lt)
GB (1) GB201403093D0 (lt)
HR (1) HRP20190685T1 (lt)
HU (1) HUE043122T2 (lt)
LT (1) LT3107914T (lt)
ME (1) ME03427B (lt)
NZ (1) NZ724323A (lt)
PL (1) PL3107914T3 (lt)
PT (1) PT3107914T (lt)
RS (1) RS58704B1 (lt)
SI (1) SI3107914T1 (lt)
TR (1) TR201905647T4 (lt)
WO (1) WO2015124941A1 (lt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR102575327B1 (ko) 2014-10-31 2023-09-07 유비이 가부시키가이샤 치환 디히드로피롤로피라졸 화합물
CA2970574C (en) 2014-12-17 2023-09-19 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rar.beta.) agonists
CN107801397B (zh) * 2015-02-13 2021-07-30 达纳-法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
MX2017016030A (es) 2015-06-15 2018-08-01 Ube Industries Derivado de dihidropirrolopirazol sustituido.
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
CN109890822B (zh) 2016-08-31 2022-08-30 安吉奥斯医药品有限公司 细胞代谢过程的抑制剂
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
MX2020001531A (es) * 2017-08-07 2020-03-20 Biocad Joint Stock Co Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
US20200197392A1 (en) * 2017-08-15 2020-06-25 The Brigham & Women's Hospital, Inc. Compositions and methods for treating tuberous sclerosis complex
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
EP3774810A1 (en) * 2018-04-11 2021-02-17 Qurient Co. Ltd. Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
US11447493B2 (en) 2018-05-02 2022-09-20 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
TW202016094A (zh) 2018-06-29 2020-05-01 美商奇奈特生物製藥公司 週期素依賴性激酶抑制劑
MA54092A (fr) * 2018-10-30 2021-09-08 Kronos Bio Inc Composés, compositions et procédés de modulation de l'activité de cdk9
US20220002303A1 (en) 2018-11-14 2022-01-06 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative
CN109860354B (zh) 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
WO2020186196A1 (en) * 2019-03-13 2020-09-17 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
CN114269742A (zh) * 2019-07-10 2022-04-01 常州千红生化制药股份有限公司 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物
US20230000870A1 (en) * 2019-10-29 2023-01-05 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
GB201918541D0 (en) * 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
EP4114528A1 (en) * 2020-03-06 2023-01-11 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
EP4282868A1 (en) * 2021-01-22 2023-11-29 Shanghai Haiyan Pharmaceutical Technology Co., Ltd Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
WO2023096922A1 (en) * 2021-11-24 2023-06-01 Kronos Bio, Inc. Polymorphic and salt forms of (ls,3s)-n1-(5-(pentan-3- yl)pyrazolo[l,5-a]pyrimidin-7-yl)cyclopentane-l,3-diamine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1242385B1 (en) 1999-12-28 2009-11-25 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
BRPI0314001B8 (pt) 2002-09-04 2021-05-25 Merck Sharp & Dohme pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas
WO2004069162A2 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2004215481B2 (en) 2003-02-28 2010-11-11 Teijin Pharma Limited Pyrazolo(1,5-A)pyrimidine derivatives
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
CN101360499B (zh) * 2005-10-06 2015-10-07 默沙东公司 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
EP2170073A4 (en) * 2007-06-05 2011-07-27 Univ Emory SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES
ES2629170T3 (es) 2009-12-04 2017-08-07 Senhwa Biosciences, Inc. Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
WO2013013188A1 (en) * 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Also Published As

Publication number Publication date
AU2015220560A1 (en) 2016-10-06
HRP20190685T1 (hr) 2019-06-14
EP3107914B1 (en) 2019-01-30
EP3107914B8 (en) 2019-07-17
AU2015220560B2 (en) 2019-05-16
BR112016018633B1 (pt) 2022-08-30
CN106103445A (zh) 2016-11-09
CN106103445B (zh) 2019-08-09
EP3107914A1 (en) 2016-12-28
US9932344B2 (en) 2018-04-03
NZ724323A (en) 2022-02-25
WO2015124941A1 (en) 2015-08-27
US11566029B2 (en) 2023-01-31
US10414772B2 (en) 2019-09-17
TR201905647T4 (tr) 2019-05-21
HUE043122T2 (hu) 2019-08-28
PL3107914T3 (pl) 2019-09-30
JP2017506250A (ja) 2017-03-02
ES2721268T3 (es) 2019-07-30
CA2939786A1 (en) 2015-08-27
RS58704B1 (sr) 2019-06-28
JP6498212B2 (ja) 2019-04-10
SI3107914T1 (sl) 2019-05-31
US20160362410A1 (en) 2016-12-15
PT3107914T (pt) 2019-05-20
GB201403093D0 (en) 2014-04-09
US20200055862A1 (en) 2020-02-20
BR112016018633A2 (lt) 2017-08-08
US20180273540A1 (en) 2018-09-27
US10927119B2 (en) 2021-02-23
CA2939786C (en) 2022-03-08
CY1121588T1 (el) 2020-05-29
DK3107914T3 (en) 2019-04-29
US20210253583A1 (en) 2021-08-19
ME03427B (me) 2020-01-20

Similar Documents

Publication Publication Date Title
HUE043122T2 (hu) Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1256751A1 (zh) [1,2,4]三唑並[1,5-a]嘧啶-7-基化合物
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
HK1254809A1 (zh) 治療中有用的吡唑並[1,5-a]三嗪-4-胺衍生物
HRP20180788T1 (hr) [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti
HK1254651A1 (zh) 吡唑並[1,5-a]嘧啶-3-甲酰胺的環醚衍生物
IL253427B (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose